Autocrine STAT3 activation in HPV positive cervical cancer through a virus-driven Rac1-NFκB-IL-6 signalling axis. by Morgan, EL & Macdonald, A
RESEARCH ARTICLE
Autocrine STAT3 activation in HPV positive
cervical cancer through a virus-driven Rac1—
NFκB—IL-6 signalling axis
Ethan L. MorganID*, Andrew MacdonaldID*
School of Molecular and Cellular Biology, Faculty of Biological Sciences and Astbury Centre for Structural
Molecular Biology, University of Leeds, Leeds, United Kingdom
* e.l.morgan@leeds.ac.uk (ELM); a.macdonald@leeds.ac.uk (AM)
Abstract
Persistent human papillomavirus (HPV) infection is the leading cause of cervical cancer.
Although the fundamental link between HPV infection and oncogenesis is established, the
specific mechanisms of virus-mediated transformation are not fully understood. We previ-
ously demonstrated that the HPV encoded E6 protein increases the activity of the proto-
oncogenic transcription factor STAT3 in primary human keratinocytes; however, the molec-
ular basis for STAT3 activation in cervical cancer remains unclear. Here, we show that
STAT3 phosphorylation in HPV positive cervical cancer cells is mediated primarily via auto-
crine activation by the pro-inflammatory cytokine Interleukin 6 (IL-6). Antibody-mediated
blockade of IL-6 signalling in HPV positive cells inhibits STAT3 phosphorylation, whereas
both recombinant IL-6 and conditioned media from HPV positive cells leads to increased
STAT3 phosphorylation within HPV negative cervical cancer cells. Interestingly, we demon-
strate that activation of the transcription factor NFκB, involving the small GTPase Rac1, is
required for IL-6 production and subsequent STAT3 activation. Our data provides new
insights into the molecular re-wiring of cancer cells by HPV E6. We reveal that activation of
an IL-6 signalling axis drives the autocrine and paracrine phosphorylation of STAT3 within
HPV positive cervical cancers cells and that activation of this pathway is essential for cervi-
cal cancer cell proliferation and survival. Greater understanding of this pathway provides a
potential opportunity for the use of existing clinically approved drugs for the treatment of
HPV-mediated cervical cancer.
Author summary
Persistent infection with HPV is the predominant cause of anogenital and oral cancers.
Transformation requires the re-wiring of signalling pathways in infected cells by virus
encoded oncoproteins. At this point, a comprehensive understanding of the full range of
host pathways necessary for HPV-mediated carcinogenesis is still lacking. In this study we
describe a signalling circuit resulting in the aberrant production of the IL-6 cytokine.
Mediated by the HPV E6 oncoprotein, it requires activation of the NFκB transcription
factor. The autocrine and paracrine actions of IL-6 are essential for STAT3 activation in
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HPV positive cervical cancers and loss of the pathway results in increased cancer cell
death and a reduction in proliferation. This study provides molecular insights into the
mechanisms by which a virus encoded oncoprotein activates an oncogenic pathway and
identifies potential targets for therapeutic intervention.
Introduction
Human papillomaviruses (HPV) are a leading cause of squamous cell carcinomas of the ano-
genital and oropharyngeal epithelium [1]. High-risk HPVs (HR-HPV), exemplified by HPV16
and 18, are responsible for >99% of cervical, and between 30–70% of oropharyngeal cancers
[2]. HR-HPVs encode three oncogenic proteins: E5, E6 and E7, which interact with a multi-
tude of host factors to manipulate signalling pathways necessary for cellular transformation.
Whilst the role of the membrane protein E5 in cellular transformation is relatively poorly
understood, it has been shown to activate EGFR signalling [3], which is necessary for transfor-
mation in vivo [4]. EGFR activation is linked to the virus-coded ion channel (viroporin) activ-
ity of E5 [5–7]. In contrast, the E6 and E7 oncoproteins have been conclusively shown to play
a pivotal role in HPV-mediated transformation [8]. The E7 protein promotes progression of
cells through the S phase of the cell cycle via an ability to bind and inactivate pocket protein
family members including pRb [9], resulting in release of the E2F transcription factor [10].
Additionally, E7 stimulates the DNA damage response, driving viral replication and genomic
instability [11,12]. HPV E6 forms complexes with host E3 ubiquitin ligases and mediates pro-
teasomal degradation of a number of host targets including the p53 tumour suppressor pro-
tein, as well as increasing telomerase activity in order to prevent apoptosis and immortalise
infected cells [13]. HR-E6 proteins also bind and regulate a selection of PSD95/DLG/ZO-1
(PDZ) domain containing proteins [14,15]. In addition to these classical interactions, emerg-
ing evidence shows targeting of additional signalling pathways, including the Wnt and Hippo
pathways, contributes to transformation by the HPV oncoproteins [16–18].
The transcription factor signal transducer and activator of transcription (STAT) 3 is an
essential regulator of cellular proliferation, differentiation and survival [19]. It is a bona fide
oncogene and its aberrant activation has been observed in a growing number of malignancies
[20]. As such, STAT3 has become an attractive therapeutic target in a diverse range of cancers,
including bladder, ovarian and head and neck squamous cell carcinoma (HNSCC) [21].
Oncogenic viruses can activate STAT3 to drive cellular proliferation, necessary for viral rep-
lication and tumourigenesis [22]. Using a primary keratinocyte cell culture model, we previ-
ously demonstrated that E6 activates STAT3 signalling during the productive HPV18 lifecycle
[23]. STAT3 activation was essential for the hyperplasia observed in HPV-containing keratino-
cyte raft culture models. Increased STAT3 protein expression and phosphorylation also corre-
lated with cervical disease progression in a panel of cytology samples [23]. Although we
identified that Janus kinase 2 (JAK2) and MAP kinases were necessary for STAT3 phosphory-
lation in HPV-containing primary keratinocytes, our understanding of the mechanisms by
which E6 mediates this process remains incomplete. Furthermore, inhibition of STAT3 activ-
ity in cervical cancer cells results in a profound reduction in cellular proliferation and the
induction of apoptosis [24,25], yet the mechanisms underpinning STAT3 activation and func-
tion in this scenario remain unknown.
A number of extracellular stimuli including cytokines and growth factors induce STAT3 phos-
phorylation and signalling [21]. This requires the phosphorylation of tyrosine 705 (Y705) and ser-
ine 727 (S727), resulting in STAT3 dimerisation and nuclear translocation, where it is able to
HPV activates STAT3
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regulate gene expression [20]. In particular, members of the IL-6 family of cytokines are key medi-
ators of STAT3 activation through their interactions with the gp130 co-receptor [26].
Here, we show that HPV positive cervical cancer cells have higher levels of phosphorylated
STAT3 protein when compared with those that are HPV negative. This results from increased
IL-6 production and release, leading to autocrine and paracrine activation of STAT3 via a sig-
nalling pathway requiring the IL-6 co-receptor gp130. Mechanistically, we show that IL-6 pro-
duction is controlled by E6-mediated stimulation of NFκB signalling, which appears to be
dependent on an upstream signalling pathway requiring the Rac1 GTPase and the AKT pro-
tein kinase. Finally, we demonstrate a correlation between NFκB activation, IL-6 expression
and cervical disease progression, suggesting that targeting the IL-6 pathway to prevent STAT3
activation may have therapeutic benefits in cervical cancer.
Results
STAT3 protein expression and phosphorylation is increased in HPV
positive compared with HPV negative cervical cancer cells
We analysed the level of STAT3 phosphorylation in a panel of six cervical cancer cell lines to estab-
lish whether HPV augmentation of STAT3 phosphorylation was evident. The panel included two
HPV negative (HPV-; C33A and DoTc2), two HPV16 positive (HPV16+; SiHa and CaSKi) and
two HPV18 positive (HPV18+; SW756 and HeLa) lines. Both HPV16+ and HPV18+ cancer cells
retained markedly higher levels of STAT3 phosphorylation at both Y705 and S727 residues com-
pared to the HPV negative cell lines (Fig 1A and 1B). The overall abundance of STAT3 protein
was also increased in the HPV positive compared with HPV negative cervical cancer cells (Fig 1A
and 1B) and this correlated with an increase in the levels of STAT3 mRNA expression in HPV pos-
itive compared to the HPV negative cell lines (Fig 1C). Together, these data demonstrate increased
levels of STAT3 expression and phosphorylation in HPV positive cervical cancer cell lines.
A secreted factor in the media of HPV positive cells can induce STAT3
phosphorylation in HPV negative cervical cancer cells
As STAT3 can be regulated by extracellular stimuli, we investigated whether HPV promotes
the secretion of factors capable of inducing STAT3 phosphorylation. C33A cells (HPV-) incu-
bated with conditioned media (CM) from HeLa (HPV18+) or CaSKi (HPV16+) cells showed
an increase in STAT3 phosphorylation on both Y705 and S727 residues over time compared
to treatment with CM from C33A cells (Fig 2A and 2B). STAT3 phosphorylation reached a
peak between 30 minutes and 1 hour (Fig 2A and 2B). This was accompanied by a significant
increase in STAT3 nuclear accumulation within C33A cells treated with HeLa or CaSKi-CM
(Fig 2C; quantified in 2D). These data indicate that a factor(s) secreted into the media from
HPV+ cells induces STAT3 phosphorylation in target cells.
IL-6 secretion is increased in HPV positive cervical cancer cells
To identify the secreted factor responsible for inducing STAT3 phosphorylation, we focused
on members of the IL-6 family of pro-inflammatory cytokines, as these have a well-studied
role in the activation of STAT3 [27]. Firstly, the mRNA expression levels of key members of
the family were measured by RT-qPCR. In both HeLa and CaSKi cells, IL6, IL10, LIF (Leukae-
mia inhibitory factor) and OSM (Oncostatin M) mRNA levels were significantly higher than
in C33A cells (Fig 3A), with IL6 showing the greatest increase. Building on this, we analysed
IL6 mRNA expression in all six cervical cancer cell lines. HPV16+ and HPV18+ cells displayed
a significantly higher level of IL6 mRNA expression compared with HPV negative cells (Fig
HPV activates STAT3
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007835 June 21, 2019 3 / 37
3B), which correlated with intracellular IL-6 protein expression analysed by western blot (Fig
3C). Finally, an IL-6 specific ELISA confirmed that HPV positive but not HPV negative cells
secreted IL-6 (Fig 3D). These data indicate that HPV positive cell lines express and secrete sig-
nificantly higher levels of IL-6 compared with HPV negative cell lines.
IL-6 binding to gp130-containing receptor complexes is required for
STAT3 phosphorylation and nuclear translocation in cervical cancer cells
IL-6 signalling is initiated by an interaction between IL-6 and the IL-6 receptor (IL-6R)–gp130
co-receptor complex [21]. IL-6 and gp130 blocking antibodies were utilised to interrogate
their requirement for STAT3 phosphorylation in cervical cancer cells. Firstly, we confirmed
that IL-6 mediated STAT3 phosphorylation in C33A cells treated with HPV positive CM by
pre-incubating with the gp130 blocking antibody before treatment. Separately, the IL-6 neu-
tralising antibody was added to CM before addition to C33A cells. Both treatments reduced
HPV positive CM induced STAT3 phosphorylation (Fig 4A) and nuclear translocation (Fig
Fig 1. STAT3 phosphorylation is higher in HPV+ verses HPV- cervical cancer cells. A) Representative western blot from six cervical cancer cell lines–two
HPV- (C33A and Dotc2 4510), two HPV16+ (SiHa and CaSKi) and two HPV18+ (SW756 and HeLa)–for the expression of phosphorylated (Y705 and S727)
and total STAT3. GAPDH served as a loading control. Data are representative of at least three biological independent repeats. B) Quantification of the protein
band intensities in A) standardised to GAPDH levels. Bars represent the means ± standard deviation from at least 3 independent biological repeats. �P<0.05,
���P<0.001 (Student’s t-test). C) Expression level of STAT3 mRNA in cervical cancer cells measured by RT-qPCR. Samples were normalized against U6
mRNA levels. Representative data are presented relative to the HPV- cervical cancer cells. Bars are the means ± standard deviation from at least three
biological repeats. ���P<0.001 (Student’s t-test).
https://doi.org/10.1371/journal.ppat.1007835.g001
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4B). Thus, IL-6 secreted from HPV positive cervical cancer cells can induce the activation of
STAT3 in HPV negative cervical cancer cells via IL-6/gp130 signalling.
To confirm that autocrine IL-6/gp130 signalling was also required for STAT3 activation in
HPV+ lines, HeLa cells were pre-incubated with IL-6 and gp130 neutralizing antibodies. Incu-
bation with either neutralising antibody reduced STAT3 dual phosphorylation and nuclear
translocation (Fig 4C and 4D), confirming an autocrine mechanism of STAT3 activation.
Together, these data demonstrate that HPV-induced IL-6 causes autocrine and paracrine acti-
vation of STAT3 signalling in cervical cell lines.
HPV E6 mediated induction of IL-6 expression is necessary and sufficient
for STAT3 phosphorylation
The increased STAT3 phosphorylation observed in HPV containing normal keratinocytes is
driven by the E6 oncoprotein [23]. Additionally, HPV16 E6 has previously been demonstrated
Fig 2. A secreted factor from HPV+ cervical cancer cells can induce STAT3 phosphorylation in HPV- cervical
cancer cells. C33A cells were serum starved for 24 hours and conditioned media from A) HeLa or B) CaSKi cells was
added for the indicated time points. For the control, C33A conditioned media was added to cells for 2 hours. Western
blots show cell lysates analysed for the expression of phosphorylated and total STAT3. GAPDH served as a loading
control. Data are representative of at least three biological independent repeats. C) C33A cells were serum starved for
24 hours and incubated with conditioned media from HeLa or CaSKi cells for 2 hours. For the control, C33A
conditioned media was added to cells for 2 hours. Cells were analysed by immunofluorescence staining for total
STAT3 (green) and counterstained with DAPI to highlight the nuclei (blue in the merged panels). Scale bar 20 μm. D)
Scatter dot plot of percentage nuclear STAT3 from C). Data represents the percentage nuclear localisation of STAT3
from 15 cells from three independent experiments. Nuclear localisation was calculated using ImageJ [92].
https://doi.org/10.1371/journal.ppat.1007835.g002
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to induce IL-6 secretion in non-small cell lung cancer (NSCLC) cells [28]. Therefore, the abil-
ity of E6 to induce IL-6 expression in cervical cells was assessed by transfection of C33A cells
with an IL-6 promoter luciferase reporter combined with either GFP-E6 or GFP expression
plasmids. Expression of HPV18 E6 significantly increased IL-6 promoter activity compared
with the GFP control (Fig 5A). This correlated with an increase in endogenous IL6 mRNA
expression (Fig 5B) and IL-6 protein expression (Fig 5C). E6 expression also resulted in a sig-
nificant increase in IL-6 secretion into the culture media (Fig 5D). To rule out the possibility
of the transformed nature of C33A cells contributing to the E6-dependent increase in IL-6 lev-
els, we also expressed HPV18 E6 in primary normal human keratinocytes (NHK). In untrans-
formed cells, E6 increased IL6 mRNA and protein expression compared to control, and this
correlated with an increase in the abundance of IL-6 protein detected in the culture media
(S1A–S1C Fig). To demonstrate that endogenous E6 could induce IL-6 expression in HPV
+ cancer cells, HeLa (Fig 5) or CaSKi (S2 Fig) cells were treated with two E6 specific siRNAs.
Knockdown of E6 led to a significant reduction in IL6 mRNA expression (Fig 5E and S2A
Fig), IL-6 protein expression (Fig 5F and S2B Fig) and secretion (Fig 5G and S2C Fig). To con-
firm that the E6-mediated activation of STAT3 by IL-6 was also working through the canonical
gp130 –IL6R receptor complex, we incubated E6 expressing cells with neutralizing antibodies
Fig 3. IL-6 is up regulated in HPV+ cervical cancer cells. A) Expression levels of cytokines from the IL-6 family were
analysed in cervical cell lines by RT-qPCR. Samples were normalized against U6 mRNA levels. Representative data are
presented relative to the HPV- cells. Bars are the means ± standard deviation from at least three biological repeats.
�P<0.05, ��P<0.01 (Student’s t-test). B) IL-6 mRNA expression in six cervical cancer cell lines analysed by RT-qPCR.
Samples were normalized against U6 mRNA levels. Representative data are presented relative to the HPV- cells. Bars
are the means ± standard deviation from at least three biological repeats. �P<0.05, ���P<0.001 (Student’s t-test). C)
Representative western blot from six cervical cancer cell lines for the expression of IL-6. GAPDH served as a loading
control. Data are representative of at least three biological independent repeats. D) ELISA analysis from the culture
medium from six cervical cancer cell lines for secreted IL-6 protein. Error bars represent the mean ± standard
deviation of a minimum of three biological repeats. ND = not determined (below the detection threshold). �P<0.05,
���P<0.001 (Student’s t-test).
https://doi.org/10.1371/journal.ppat.1007835.g003
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Fig 4. Autocrine/paracrine IL-6 signalling induces STAT3 phosphorylation and nuclear translocation in cervical cancer cell lines.
A) Representative western blot of C33A cells treated with conditioned medium (CM) from HeLa and CaSKi cells for 2 hours. Cells
were pre-treated with IgG, anti-IL6 or anti-gp130 antibody for 4 hours before CM addition. Cell lysates were analysed for
phosphorylated and total STAT3 expression. GAPDH served as a loading control. Data are representative of at least three biological
HPV activates STAT3
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against gp130 and IL-6. As expected, incubation with either antibody led to a reduction in the
E6-mediated phosphorylation of STAT3 (Fig 5H). Activation of STAT3 by HPV18 E6 is inde-
pendent of interactions with E6AP, p53 and cellular PDZ domains [23]. To address whether
IL-6 production requires these functions, wildtype and mutant HPV18 E6 proteins deficient in
their ability to bind p53, E6AP or PDZ domains were expressed in C33A cells. As predicted,
independent repeats. B) C33A cells treated with conditioned medium (CM) from HeLa and CaSKi cells for 2 hours. Cells were pre-
treated with IgG, anti-IL6 or anti-gp130 antibody for 4 hours before CM addition. Cells were then analysed by immunofluorescence
staining for total STAT3 (green) and counterstained with DAPI to highlight the nuclei (blue in the merged panels). Scale bar 20 μm.
Quantification of nuclear STAT3 is shown below. C) HeLa cells were treated with IgG, anti-IL6 or anti-gp130 for 4 hours. Cell lysates
were analysed for phosphorylated and total STAT3 expression. GAPDH served as a loading control. Data are representative of at least
three biological independent repeats. D) HeLa cells were treated with IgG, anti-IL6 or anti-gp130 for 4 hours. Cells were then analysed
by immunofluorescence staining for total STAT3 (green) and counterstained with DAPI to highlight the nuclei (blue in the merged
panels). Scale bar 20 μm. Quantification of nuclear STAT3 is shown below.
https://doi.org/10.1371/journal.ppat.1007835.g004
Fig 5. HPV18 E6 induced IL-6 expression is required for STAT3 phosphorylation. A) Representative luciferase reporter assay from C33A cells co-transfected
with GFP tagged HPV18 E6 and an IL-6 promoter reporter. Promoter activity was measured using a dual-luciferase system. Data are presented as relative to the
GFP transfected control. B) C33A cells were transiently transfected with GFP or GFP tagged HPV18 E6 and RNA was extracted for RT-qPCR analysis of IL-6
expression. Samples were normalized against U6 mRNA levels. Data are presented relative to the GFP control. C) Representative western blot of C33A cells
transiently transfected with GFP or GFP tagged HPV18 E6 and analysed for IL-6 expression. Expression of HPV E6 was confirmed using a GFP antibody and
GAPDH served as a loading control. D) C33A cells were transiently transfected with GFP or GFP tagged HPV18 E6. The culture medium was analysed for IL-6
protein by ELISA. E) HeLa cells were transfected with a pool of two specific siRNAs targeting HPV18 E6 and analysed for IL-6 mRNA expression by RT-qPCR.
Samples were normalized against U6 mRNA levels. F) Representative western blot of HeLa cells transfected with a pool of two specific siRNAs targeting HPV18
E6 and analysed for the expression of IL-6. Knockdown of HPV18 E6 was confirmed using an antibody against HPV18 E6 and p53. GAPDH served as a loading
control. G) HeLa cells were transfected with a pool of two specific siRNAs against HPV18 E6. The culture medium was analysed for IL-6 protein by ELISA. H)
Representative western blot of C33A cells transiently transfected with GFP or GFP tagged HPV18 E6 and treated with IgG, anti-IL6 or anti-gp130 for 4 hours
before harvest. Cell lysates were then analysed for phosphorylated and total STAT3. Expression of HPV E6 was confirmed using a GFP antibody and GAPDH
served as a loading control. Bars represent the means ± standard deviation from at least three independent biological repeats. �P<0.05, ��P<0.01, ���P<0.001
(Student’s t-test).
https://doi.org/10.1371/journal.ppat.1007835.g005
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the mutant E6 proteins increased IL-6 protein expression to levels similar as wildtype (S3 Fig).
Together, these data demonstrate that IL-6 expression and secretion are increased by a mecha-
nism independent of the p53 destabilising, and PDZ binding functions, of E6.
HR-HPV E6 activates NFκB to induce IL-6 expression
The NFκB transcription factor is an important regulator of IL-6 expression, which is activated
in response to a range of extracellular ligands such as TNFα [29]. HR-E6 has previously been
shown to activate NFκB signalling under hypoxic conditions [30,31]. However, to assess
whether NFκB is necessary for increased IL-6 expression under normoxic conditions, we first
tested whether expression of HPV18 E6 in isolation would activate NFκB in C33A cells. Using
an NFκB driven luciferase reporter plasmid, overexpression of E6 induced NFκB activity com-
pared to a GFP control (Fig 6A). Canonical NFκB signalling results in the phosphorylation of
the p65 subunit and its nuclear translocation, where it is transcriptionally active in complex
with additional NFκB subunits including p50 [29]. E6 over-expression in C33A or NHK cells
induced robust p65 phosphorylation, without affecting total p65 protein levels (Fig 6B). In
contrast, siRNA knockdown of E6 in HeLa cells reduced p65 phosphorylation (Fig 6C),
together suggesting that HPV E6 activates canonical NFκB.
To understand the role of NFκB in E6-driven IL-6 production, we employed a dual
approach to prevent NFκB activation in C33A cells overexpressing HPV18 E6. Cells were
treated either with a small molecule inhibitor (IKKi) targeting the IKKα/β complex, which
phosphorylates and activates NFκB, or transfected with a plasmid encoding a mutant IκBα
protein (IκBm), which cannot be degraded and as such retains inactive NFκB in the cytosol
[32]. Inhibition of NFκB using either IKKi or IκBm led to a significant reduction in E6-medi-
ated IL6 mRNA expression (Fig 6D), IL-6 protein levels (Fig 6E) and secretion (Fig 6F).
Importantly, both strategies effectively inhibited NFκB activity as judged by a reduction in p65
phosphorylation (Fig 6E).
We also tested if NFκB activity was required for mediating the increased IL-6 levels seen in
HeLa and CaSKi cells. In these cells, inhibition of NFκB led to a reduction in IL6 mRNA
expression, IL-6 protein levels and secretion (Fig 6G–6I). Collectively, these data demonstrate
that HR-E6-mediated IL-6 expression requires active NFκB.
NFκB is required for STAT3 phosphorylation in HR-E6 expressing cells
It was necessary to test whether NFκB was also needed for the activation of STAT3. As proof
of principle, we tested the ability of the NFκB activator TNFα to induce STAT3 phosphoryla-
tion. As expected, treatment of serum starved C33A cells with TNFα caused robust p65 phos-
phorylation, which peaked at 0.5 hours after treatment (S4 Fig). This was coupled with an
increase in IL-6 expression, which remained high up to 24 hours post treatment. Importantly,
TNFα treatment also caused an increase in STAT3 phosphorylation and nuclear translocation,
observed to peak approximately 2 hours post treatment (S4A and S4B Fig).
We next set out to link NFκB activation by E6 to STAT3 phosphorylation. For this, HPV18
E6 was overexpressed in C33A cells, with or without treatment with the NFκB inhibitor IKKi,
or co-expression of IκBm. E6 noticeably increased the levels of p65 and STAT3 phosphoryla-
tion and inhibition of NFκB by either approach reduced STAT3 phosphorylation (Fig 7A).
Blockade of NFκB activity also reduced STAT3 phosphorylation in HeLa (Fig 7B and 7C) and
CaSKi (S5A and S5B Fig) cells, suggesting that E6 mediated STAT3 phosphorylation is
depended on NFκB activity. To ascertain if NFκB was essential for the paracrine activation of
STAT3 in C33A cells, we took CM from HeLa cells in which NFκB was inhibited and added
this to C33A cells. This failed to induce STAT3 phosphorylation (Fig 7D) and nuclear
HPV activates STAT3
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Fig 6. HPV E6 mediated IL-6 expression requires active NFκB. A) Representative luciferase reporter assay from C33A cells co-transfected with GFP tagged E6
and a ConA reporter containing tandem κB binding sites [93]. Promoter activity was measured using a dual-luciferase system. Data are presented as relative to
the GFP transfected control. B) Representative western blot of C33A and normal human keratinocytes (NHK) cells transiently transfected with GFP or GFP
tagged HPV18 E6 and analysed for phosphorylated and total p65 expression. Expression of HPV E6 was confirmed using a GFP antibody in the C33A cells. In
NHK cells an antibody directly detecting HPV18 E6 was used to confirm expression of the GFP E6 fusion protein. GAPDH served as a loading control. C)
Representative western blot of HeLa cells transfected with a pool of two specific siRNAs targeting HPV18 E6 and analysed for the expression of phosphorylated
and total p65. Knockdown of HPV18 E6 was confirmed using an antibody against HPV18 E6 and p53. GAPDH served as a loading control. D-F) C33A cells
were co-transfected with GFP, GFP tagged HPV18 E6 or GFP tagged HPV18 E6 and mutant IκBα (IκBm). Cells were then either left untreated or treated with
IKK inhibitor VII (IKKi). D) Total RNA was extracted for RT-qPCR analysis of IL-6 expression. Samples were normalized against U6 mRNA levels.
Representative data are presented relative to the GFP control. E) Cell lysates were analysed for the expression of phosphorylated and total p65 and IL-6.
Expression of HPV E6 was confirmed using a GFP antibody and GAPDH served as a loading control. F) The culture medium was analysed for IL-6 protein by
ELISA. G-I) HeLa and CaSKi cells were transfected with mutant IκBα (IκBm) or treated with IKK inhibitor VII (IKKi). G) Total RNA was extracted for RT-
qPCR analysis of IL-6 expression. Samples were normalized against U6 mRNA levels. Representative data are presented relative to the DMSO or pcDNA control.
H) Cell lysates were analysed for the expression of phosphorylated and total p65 and IL-6. GAPDH served as a loading control. I) The culture medium was
HPV activates STAT3
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translocation (Fig 7E; quantified in S6A Fig). Importantly, inhibition of NFκB activity had no
effect on STAT3 nuclear translocation mediated by treatment with exogenous IL-6 (Fig 7F;
quantified in S6B Fig), demonstrating that NFκB is upstream of IL-6 secretion. Together, these
data suggest that NFκB is required for the autocrine and paracrine activation of STAT3.
The protein kinase AKT is activated by HR-E6 and contributes to NFκB
activation and IL-6 production
NFκB is activated by multiple upstream signalling components in a stimulus and tissue-depen-
dent manner [33]. In searching for upstream activators, we initially focused on known targets
of HR-E6 with a link to NFκB signalling. The PI3K/AKT signalling pathway is frequently acti-
vated in cervical cancers due to mutations in the PIK3CA gene [34], and AKT can activate
NFκB and mediate IL-6 expression in some cancers [35–37]. Finally, AKT has previously been
shown to be activated by E6 [38]. We therefore tested whether AKT was involved in NFκB
activation and IL-6 secretion in HPV positive cervical cancer cell lines. First, we confirmed
that E6 activates AKT, as measured by an increase in AKT phosphorylation. Over expression
of HPV18 E6 in C33A and NHK cells led to a marked increase in AKT phosphorylation at
both threonine 308 and serine 473, without affecting levels of total AKT protein (Fig 8A). Con-
versely, siRNA knockdown of E6 in HeLa cells reduced AKT phosphorylation (Fig 8B), con-
firming that HPV18 E6 activates AKT.
To interrogate the contribution of AKT activation to IL-6 production, E6 expressing cells
were treated either with a potent allosteric inhibitor of AKT (AKTi), targeting the AKT1 and 2
isoforms [39] or transfected with a plasmid encoding a catalytically inactive AKT mutant
(AKT-DN) [40]. Inhibition of AKT by either approach led to a statistically significant reduc-
tion in IL6 mRNA expression (Fig 8C), coupled to a smaller loss in protein expression and
secretion (Fig 8D and 8E). To confirm that the AKT-mediated increase in IL-6 was transduced
via NFκB, we measured p65 phosphorylation levels in E6 expressing C33A cells treated with
either AKTi or co-transfected with AKT-DN. As expected, a loss of AKT phosphorylation was
observed, indicating that the inhibition strategy was successful, and this was coupled with a
reduction in IL-6 protein expression (Fig 8D) and a partial reduction in p65 phosphorylation,
suggesting that AKT lies upstream of NFκB in the regulation of IL-6.
We also validated the impact of AKT inhibition on IL-6 production in both HeLa and
CaSKi cells. Interestingly, inhibition of AKT in CaSKi cells had a greater effect in reducing IL6
mRNA expression (Fig 8F), IL-6 protein levels (Fig 8G) and secretion (Fig 8H) than in HeLa
cells. Furthermore, AKT inhibition led to a greater reduction in p65 phosphorylation in CaSKi
cells (Fig 8G). These data confirm that AKT contributes to IL-6 production through the regu-
lation of NFκB. Strikingly, there appear to be cell line differences in the requirement for AKT,
with ablation of AKT kinase activity having a more significant impact on signalling in CaSKi
than in HeLa cells.
AKT contributes to STAT3 phosphorylation in cells expressing E6 and in
HPV positive cervical cell lines
Based on the observation that inhibition of AKT reduced IL-6 production, particularly in
CaSKi cells, we tested whether blockade of AKT activity would also impact on STAT3 phos-
phorylation. HPV18 E6 expressing C33A cells treated with AKTi or co-expressing AKT-DN
analysed for IL-6 protein by ELISA. Bars represent the means ± standard deviation from at least three independent biological repeats. �P<0.05, ��P<0.01,
���P<0.001 (Student’s t-test).
https://doi.org/10.1371/journal.ppat.1007835.g006
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Fig 7. Active NFκB is required for HPV E6 mediated STAT3 signalling. A) C33A cells were co-transfected with GFP, GFP tagged HPV18 E6 or GFP tagged
HPV18 E6 and mutant IκBα (IκBm). Cells were then either left untreated or treated with IKK inhibitor VII (IKKi). Cell lysates were analysed for phosphorylated
and total p65, phosphorylated and total STAT3 expression. Expression of HPV E6 was confirmed using a GFP antibody and GAPDH served as a loading control.
B) Representative western blot of HeLa cells treated with increasing doses of the IKKα/β inhibitor IKK inhibitor VII (IKKi). Cell lysates were analysed for the
expression of phosphorylated and total p65, phosphorylated and total STAT3 and IL-6 expression. GAPDH served as a loading control. C) Representative western
blot of HeLa cells transfected with mutant IκBα (IκBm). Cell lysates were analysed as in B). D) C33A cells were serum starved for 24 hours. Cells were then treated
with HeLa conditioned media for 2 hours from HeLa cells treated with DMSO or IKKi or transfected with pcDNA or IκBm. Cell lysates were analysed for
phosphorylated and total STAT3 expression. GAPDH served as a loading control. E) C33A cells were serum starved for 24 hours. Cells were then treated with
HeLa condition media for 2 hours from HeLa cells treated with DMSO or IKKi or transfected with pcDNA or IκBm. Cells were analysed by immunofluorescence
staining for total STAT3 (green) and counterstained with DAPI to highlight the nuclei (blue in the merged panels). Scale bar 20 μm. F) C33A were treated with
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showed a loss of AKT phosphorylation coupled to a modest reduction in STAT3 phosphoryla-
tion at both residues (Fig 9A). Levels of STAT3 phosphorylation were also measured in HeLa
and CaSKi cells treated with increasing concentrations of AKTi or over-expressing the
AKT-DN protein. Whilst these inhibitory strategies reduced AKT phosphorylation in both cell
lines, the corresponding reduction in STAT3 phosphorylation in HeLa cells was minor and
mirrored the small reduction in IL-6 protein expression (Fig 9B and 9C). In contrast, loss of
AKT activity corresponded with a greater reduction in IL-6 expression and STAT3 phosphory-
lation in CaSKi cells (S7A and S7B Fig). To ascertain if AKT was essential for the paracrine
activation of STAT3 in C33A cells, we took CM from HeLa cells in which AKT was inhibited
either by treatment with AKTi or co-expression of AKT-DN and added this to C33A cells. CM
from cells with inhibited AKT caused less STAT3 phosphorylation (Fig 9D) and nuclear trans-
location (Fig 9E; quantified in S8A Fig) compared to controls. Importantly, inhibition of AKT
activity had no effect on STAT3 nuclear translocation mediated by exogenous IL-6 (Fig 9F;
quantified in S8B Fig), demonstrating that AKT is upstream of IL-6 secretion. Together, these
data suggest that AKT is an E6 effector playing a minor role in the autocrine and paracrine
activation of STAT3.
Rac1 mediates NFκB activation and IL-6 production in HPV positive
cervical cancer cells
Whilst our data points to a role for AKT as an E6-effector protein with the potential to activate
NFκB and IL-6 production, it is clear that other cellular factors are required and likely play a
more prominent role in the signalling pathway. As part of our efforts to identify such candi-
dates, we investigated the possible involvement of the small GTPase Rac1 as it has previously
been shown to regulate both AKT and STAT3 signalling [41–44]. In addition, Rac1 is active in
a number of skin and oral SCCs, and experiments from mouse models suggest that it acts as a
proto-oncogene [45–47]. Rac1 can facilitate papilloma formation in HPV negative 8 transgenic
mice [48] and is active in HPV-mediated respiratory papillomatosis [49,50]. We therefore
measured the levels of active Rac1 (Rac1-GTP) in E6-expressing C33A cells using an affinity
precipitation assay [51]. Expression of HPV18 E6 increased Rac1-GTP levels compared with
control cells (Fig 10A) and siRNA depletion of E6 from HeLa cells resulted in a reduction in
active Rac1 compared to a scramble control (Fig 10B). Together, these data indicate that E6
activates Rac1.
We next set out to determine if the Rac1 GTPase links E6 to IL-6 production. To this end
we used two well characterised approaches to inhibit Rac1 function. C33A cells expressing
HPV18 E6 were treated with the Rac1 inhibitor NSC23766 (NSC) or co-transfected with a
transdominant mutant Rac1 (Rac1 T17N - Rac1-DN) and IL-6 mRNA levels were measured
by RT-qPCR. Inhibition of Rac1 activity with either NSC or Rac1-DN potently inhibited IL-6
mRNA expression in E6 expressing cells (Fig 10C). Inhibition of Rac1 function also impaired
E6-induced p65 phosphorylation, supporting a role for Rac1 in the E6 stimulation of NFκB
(Fig 10D). Rac1 inhibition was accompanied by a significant reduction in IL-6 protein expres-
sion and secretion into the culture media (Fig 10D and 10E). Active Rac1 was also critical for
p65 phosphorylation, IL6 mRNA expression and IL-6 protein expression and secretion in both
HeLa and CaSKi cells (Fig 10F–10H). We also noted that blockade of Rac1 function reduced
AKT dual phosphorylation either in cells expressing HPV18 E6 in isolation or in HPV positive
DMSO or IKKi or transfected with pcDNA or IκBm before treatment with 20 ng/mL recombinant human IL-6 for 30 mins. Cells were analysed by
immunofluorescence staining for total STAT3 (green) and counterstained with DAPI to highlight the nuclei (blue in the merged panels). Scale bar 20 μm.
https://doi.org/10.1371/journal.ppat.1007835.g007
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Fig 8. Activation of AKT by HPV E6 contributes to IL-6 expression via NFκB. A) Representative western blot of C33A and NHK cells transiently
transfected with GFP or GFP tagged HPV18 E6 and analysed for phosphorylated and total AKT expression. Expression of HPV E6 was confirmed in C33A
cells using a GFP antibody and in NHK cells using a HPV18 E6 antibody. GAPDH served as a loading control. B) Representative western blot of HeLa cells
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cervical cancer cells (Fig 10D and 10G). Collectively the results indicate a key role for Rac1 in
E6-regulated IL-6 production upstream of AKT and NFκB.
Rac1 activates STAT3 by an IL-6-dependent mechanism
We examined whether Rac1 was also necessary for STAT3 activation by E6. Chemical inhibi-
tion of Rac1 or over-expression of the Rac1-DN mutant decreased the dual phosphorylation of
STAT3 in HPV18 E6 expressing C33A cells (Fig 11A). Similarly, NSC addition to HeLa (Fig
11B) or CaSKi (S9A Fig) resulted in a dose-dependent decrease in STAT3 phosphorylation.
Confirmatory results were obtained in cells overexpressing the transdominant Rac1 mutant
(Fig 11C and S9B Fig). To explore if Rac1 contributed to the paracrine activation of STAT3 in
C33A cells, we took CM from HeLa cells in which Rac1 was inhibited and added this to C33A
cells. This failed to induce STAT3 phosphorylation (Fig 11D) and nuclear translocation (Fig
11E; quantified in S10A Fig). Crucially, Rac1 inhibition had negligible effect on STAT3 nuclear
translocation mediated by treatment with exogenous IL-6 (Fig 11F; quantified in S10B Fig),
demonstrating that Rac1 is upstream of IL-6 secretion.
STAT3 is required for HPV positive cervical cancer cell proliferation
STAT3 is a key mediator of cell proliferation [52,53]. Given this information it was pertinent
to investigate the consequences of inhibiting STAT3 activation in HPV positive cervical cancer
cells by the application of two chemically distinct inhibitors of STAT3 (cryptotanshinone and
S3I-201) or by transfecting cells with a pool of STAT3 specific siRNA [23]. Growth curves
were performed with HeLa and CaSKi cells treated with DMSO or STAT3 inhibitors or trans-
fected with scramble or STAT3 specific siRNA. Compared to controls, blockade of STAT3
activity or loss of its expression resulted in a significant reduction in cell growth over the time
course of treatment (Fig 12A and 12B). Additionally, treatment with STAT3 inhibitors or
depletion of STAT3 protein suppressed the ability of HeLa and CaSKi cells to form colonies
under anchorage-dependent (Fig 12C and 12D) and anchorage-independent (Fig 12E and
12F) conditions. To further evaluate the impact of STAT3 inhibition, we assessed the levels of
key cell cycle proteins. STAT3 phosphorylation was decreased when treated with increasing
concentrations of cryptotanshinone (Fig 12G) and this correlated with a decrease in cyclin D1
expression, which we previously identified as a STAT3 target in HPV-containing primary ker-
atinocytes [23]. Loss of cyclin D1 expression was associated with an increase in the levels of the
cyclin dependent kinase inhibitor p21WAF1/KIP1 (Fig 12G). Changes to the complement of cell
cycle control proteins as a result of STAT3 inhibition correlated with a loss in HPV oncopro-
tein expression in both HeLa and CaSKi cells (Fig 12G). Similar effects on cyclin D1, p21
and HPV oncoprotein expression were observed in cells treated with STAT3-specific siRNA
(Fig 12H).
transfected with a pool of two specific siRNAs against HPV18 E6 and analysed for the expression of phosphorylated and total AKT. Knockdown of HPV18
E6 was confirmed using an antibody against HPV18 E6 and p53. GAPDH served as a loading control. C-E) C33A cells were co-transfected with GFP, GFP
tagged HPV18 E6 or GFP tagged HPV18 E6 and dominant negative AKT (AKT-DN). Cells were either left untreated or treated with AKT inhibitor VIII
(AKTi). C) Total RNA was extracted for RT-qPCR analysis of IL-6 expression. Samples were normalized against U6 mRNA levels. Representative data are
presented relative to the GFP control. D) Cell lysates were analysed for the expression of phosphorylated and total p65 and AKT and IL-6 protein.
Expression of HPV E6 was confirmed using a GFP antibody, the AKT-DN was detected using an antibody against the FLAG epitope and GAPDH served as
a loading control. E) The culture medium was analysed for IL-6 protein by ELISA F-H) HeLa and CaSKi cells transfected with AKT-DN or treated with
AKTi. F) Total RNA was extracted for RT-qPCR analysis of IL-6 expression. Samples were normalized against U6 mRNA levels. Representative data are
presented relative to the GFP control. G) Cell lysates were analysed for the expression of phosphorylated and total p65 and AKT and IL-6 protein.
Expression of HPV E6 was confirmed using a GFP antibody and AKT-DN using the FLAG epitope. GAPDH served as a loading control. H) The culture
medium was analysed for IL-6 protein by ELISA. Bars represent the means ± standard deviation from at least three independent biological repeats. �P<0.05,
��P<0.01, ���P<0.001 (Student’s t-test).
https://doi.org/10.1371/journal.ppat.1007835.g008
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Fig 9. Active AKT contributes to HPV E6 mediated STAT3 signalling. A) C33A cells were co-transfected with GFP, GFP tagged HPV18 E6 or GFP tagged
HPV18 E6 and dominant negative AKT (AKT-DN). Cells were then either left untreated or treated with AKT inhibitor VIII (AKTi). Cell lysates were analysed
for phosphorylated and total AKT, and phosphorylated and total STAT3 expression. Expression of HPV E6 was confirmed using a GFP antibody and GAPDH
served as a loading control. B) Representative western blot of HeLa cells treated with increasing doses of the AKTi. Cell lysates were analysed for the expression
of phosphorylated and total AKT, phosphorylated and total STAT3 and IL-6 expression. GAPDH served as a loading control. C) Representative western blot of
HeLa cells transfected with dominant negative AKT (AKT-DN). Cell lysates were analysed as in B). D) C33A cells were serum starved for 24 hours. Cells were
then treated with HeLa conditioned media for 2 hours from HeLa cells treated with DMSO or AKTi or transfected with pcDNA or AKT-DN. Cell lysates were
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These observations prompted us to explore whether upstream components in the STAT3
activation pathway are also necessary for HPV positive cancer cell proliferation. To this end
colony formation assays were used to measure anchorage-dependent growth of HeLa and
CaSKi cells in which NFκB was inhibited either by treatment with the IKKi small molecule
inhibitor or by over-expression of the transdominant IκBa protein. NFκB inhibition signifi-
cantly reduced the ability of HPV positive cancer cells to form colonies (S11A Fig). Next, we
tested the upstream activators of NFκB. Blockade of Rac1 activity with the NSC compound or
overexpression of Rac1-DN was detrimental to HPV positive cancer cell proliferation and
resulted in approximately 50% fewer colonies than the controls (S11B Fig). Finally, we assessed
the contribution of AKT to HPV positive cancer cell proliferation. Loss of active AKT, either
as a result of AKTi treatment or overexpression of the catalytically inactive AKT mutant, also
impaired cell proliferation (S11C Fig). Similar differences in anchorage-independent growth
were observed when these proteins were perturbed (S11D and S11E Fig). When compared,
loss of Rac1 and NFκB activity reduced proliferation in both HeLa and CaSKi cells, whilst the
impact of AKT inhibition was more pronounced in the CaSKi cells. Collectively, these observa-
tions provide evidence that the STAT3 activation pathway is crucial for HPV positive cancer
cell proliferation.
STAT3 is necessary for HPV positive cancer cell survival
In light of the impact of STAT3 inhibition on HPV+ cervical cancer cell proliferation, we
sought to address whether the absence of active STAT3 induced apoptosis. STAT3 activity was
inhibited in HeLa and CaSKi cells by treatment with STAT3 small molecule inhibitors for 6
and 24 hours (Fig 13A) or STAT3 protein depleted by transfection of a pool of STAT3-specific
siRNA (Fig 13B), and the degree of phosphatidylserine exposure on the plasma membrane
measured by Annexin V stain. At both 6 and 24 hours post treatment, inhibition of STAT3 or
loss of STAT3 protein led to a significant increase in apoptosis compared to controls in both
cell lines. We next demonstrated the activation of caspase 3 by measuring the degree of cleav-
age of the caspase 3 substrate poly(ADP) ribose polymerase (PARP) by western blot. As
shown, inhibition of STAT3 activity (Fig 13C) or loss of STAT3 protein (Fig 13D) promoted
the appearance of the faster migrating, proteolytically cleaved, form of PARP. Appearance of
cleaved PARP was coincident with reduced expression of the anti-apoptotic Bcl-2 family pro-
tein Bcl-XL. RT-qPCR revealed the loss of survival factors such as Bcl-XL (bcl2l1) and Survivin
(birc5) to be at the transcriptional level (Fig 13E and 13F). Thus, STAT3 is essential for HPV
+ cervical cancer cell survival.
STAT3 and IL-6 engage in an autocrine positive feedback loop in HPV
positive cervical cancer cells
STAT3 has been shown to engage in mechanisms to augment NFκB activation and maintain
IL-6 expression in a number of cancers and inflammatory disorders [54–57]. To investigate if
such a positive feedback loop exists in cervical cancer cells we used siRNA to deplete STAT3
from HeLa and CaSKi cells and then measured the impact on IL-6 expression (S12 Fig). Upon
analysed for phosphorylated and total STAT3 expression. GAPDH served as a loading control. E) C33A cells were serum starved for 24 hours. Cells were then
treated with HeLa condition media for 2 hours from HeLa cells treated with DMSO or AKTi or transfected with pcDNA or AKT-DN. Cells were analysed by
immunofluorescence staining for total STAT3 (green) and counterstained with DAPI to highlight the nuclei (blue in the merged panels). Scale bar 20 μm. F)
C33A were treated with DMSO or AKTi or transfected with pcDNA or AKT-DN before treatment with 20 ng/mL recombinant human IL-6 for 30 mins. Cells
were analysed by immunofluorescence staining for total STAT3 (green) and counterstained with DAPI to highlight the nuclei (blue in the merged panels). Scale
bar 20 μm.
https://doi.org/10.1371/journal.ppat.1007835.g009
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Fig 10. Rac1 is upstream of AKT/NFκB in HPV E6 mediated IL-6 production. A) Representative western blot of C33A cells transiently transfected with
GFP or GFP tagged HPV18 E6 and analysed for active Rac1 using a Rac1 activity assay. Expression of HPV E6 was confirmed using a GFP antibody.
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STAT3 depletion we observed a marked reduction in the levels of IL-6 mRNA, IL-6 protein
expression and secretion, indicating that STAT3 likely drives a mechanism to maintain
enhanced IL-6 expression in cervical cancer cells.
IL-6 expression correlates with cervical disease progression
The IL-6—STAT3 signalling axis has emerged as a key contributor to carcinogenesis in a num-
ber of cancers [21], often resulting in increased IL-6 expression as observed in lung cancer and
head and neck cancers [58,59]. We analysed cervical liquid-based cytology samples from a
cohort of HPV16+ patients representing the progression of disease development (CIN1-CIN3)
and compared this to HPV- normal cervical tissue to explore the role of IL-6 in cervical dis-
ease. Firstly, we observed an increase in the levels of IL6 mRNA expression, which correlated
with disease progression through CIN1-CIN3 (Fig 14A), with the greatest increase observed in
CIN3 samples when compared with normal cervical tissue. Importantly, we also noted an
increase in IL-6 protein levels, which correlated with disease progression (Fig 14B), again
showing the largest increase in CIN3. Analysis of a larger cohort of clinical samples revealed a
breadth in the levels of IL-6 protein expression, particularly in the CIN3 samples, which sepa-
rated into 2 subsets; IL-6 high (n = 9; 45%) and IL-6 low (n = 11; 55%) (Fig 14C, left). To view
the spread of IL-6 expression, we performed a Box and Whisker plot analysis (Fig 14C, right).
The data clearly show that despite the presence of IL-6 outliers, levels of IL-6 protein expres-
sion are higher in the majority of CIN3 samples, with the IL-6 low subset still significantly
higher when compared to healthy controls. To corroborate these findings in primary tumours,
we mined an available microarray database of normal cervical samples against cervical cancer
samples and revealed a statistically significant increase in IL6 mRNA expression in the cervical
cancer samples (Fig 14D). As with our analysis of CIN, IL-6 expression in the cervical cancer
cases clearly separates into 2 subsets; IL-6 high (n = 7; 25.9%) and IL-6 low (n = 20; 74.1%). As
our mechanistic analysis revealed a significant role for NFκB in IL-6 production, we wished to
determine whether expression and activation of this critical transcription factor was also
increased in the patient samples available. Western blot analysis revealed an increase in both
the levels of total and phosphorylated p65 protein that correlated with disease progression (Fig
14B). Quantification of the larger cohort of cytology samples showed that this increase was sta-
tistically significant (Fig 14E–14G). Together, these data demonstrate that p65 and IL-6 levels
are increased in HPV associated cervical disease.
Discussion
Oncogenic viruses can activate STAT3 to increase cell proliferation, enhance viral replication
and this ultimately can contribute to tumourigenesis [22]. Previously, we used a primary cell
culture model to show that the E6 oncoprotein activates STAT3 signalling in primary
GAPDH served as a loading control. B) Representative western blot of HeLa cells transfected with a pool of two siRNAs targeting HPV18 E6 and analysed
for active Rac1 using a Rac1 activity assay. Knockdown of HPV18 E6 was confirmed using an antibody against HPV18 E6 and p53. GAPDH served as a
loading control. C-E) C33A cells were co-transfected with GFP, HA tagged HPV18 E6 alone or co-transfected with Rac1 N17 (Rac1-DN). Cells were then
either left untreated or treated with the Rac1 inhibitor NSC23866 (NSC). C) Total RNA was extracted for RT-qPCR analysis of IL-6 expression. Samples
were normalized against U6 mRNA levels. Representative data are presented relative to the GFP control. D) Cell lysates were analysed for the expression of
phosphorylated and total p65, phosphorylated and total AKT and IL-6 protein. Expression of HPV E6 was confirmed using a HA antibody, Rac1-DN
expression was confirmed using a GFP antibody and GAPDH served as a loading control. E) The culture medium was analysed for IL-6 protein by ELISA.
F-H) HeLa and CaSki cells transfected with Rac1-DN or treated with NSC. F) Total RNA was extracted for RT-qPCR analysis of IL-6 expression. Samples
were normalized against U6 mRNA levels. Representative data are presented relative to the GFP control. G) Cell lysates were analysed for the expression of
phosphorylated and total p65, phosphorylated and total AKT and IL-6. Expression of Rac1-DN was confirmed using a GFP antibody and GAPDH served
as a loading control. H) The culture medium was analysed for IL-6 protein by ELISA. Bars represent the means ± standard deviation from at least three
independent biological repeats. �P<0.05, ��P<0.01, ���P<0.001 (Student’s t-test).
https://doi.org/10.1371/journal.ppat.1007835.g010
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Fig 11. Rac1 is required for HPV E6 mediated IL-6/STAT3 signalling. A) C33A cells were co-transfected with GFP, HA tagged HPV18 E6 or HA tagged
HPV18 E6 and Rac1-DN. Cells were then either left untreated or treated with the Rac1 inhibitor NSC23866 (NSC). Cell lysates were then analysed for
phosphorylated and total STAT3 expression. Expression of HPV E6 was confirmed using a HA antibody, Rac1-DN expression was confirmed using a GFP
antibody and GAPDH served as a loading control. B) Representative western blot of HeLa cells treated with increasing doses of the NSC. Cell lysates were
analysed for the expression of phosphorylated and total STAT3 and IL-6 expression. GAPDH served as a loading control. C) Representative western blot of HeLa
cells transfected with Rac1-DN. Cell lysates were analysed as in B). D) C33A cells were serum starved for 24 hours. Cells were then treated with HeLa
conditioned media for 2 hours from HeLa cells treated with DMSO or NSC or transfected with GFP or Rac1-DN. Cell lysates were analysed for phosphorylated
and total STAT3 expression. GAPDH served as a loading control. E) C33A cells were serum starved for 24 hours. Cells were then treated with HeLa condition
media for 2 hours from HeLa cells treated with DMSO or NSC or transfected with GFP or Rac1-DN. Cells were analysed by immunofluorescence staining for
total STAT3 (green) and counterstained with DAPI to highlight the nuclei (blue in the merged panels). Scale bar 20 μm. F) C33A were treated with DMSO or
NSC or transfected with GFP or Rac1-DN before treatment with 20 ng/mL recombinant human IL-6 for 30 mins. Cells were analysed by immunofluorescence
staining for total STAT3 (green) and counterstained with DAPI to highlight the nuclei (blue in the merged panels). Scale bar 20 μm.
https://doi.org/10.1371/journal.ppat.1007835.g011
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Fig 12. STAT3 is required for the proliferation of HPV+ cervical cancer cells. A) Growth curve analysis of HeLa (left) and CaSKi (right) cells after addition of small
molecule STAT3 inhibitors for 24 hours. B) Growth curve analysis of HeLa (left) and CaSKi (right) cells after transfection of a pool of four specific STAT3 siRNA for
72 hours. C) Colony formation assay (anchorage dependent growth) of HeLa and CaSKi cells after the addition of inhibitors for 24 hours. D) Colony formation assay
(anchorage dependent growth) of HeLa and CaSKi cells after transfection of a pool of four specific STAT3 siRNA for 72 hours. E) Soft agar assay of HeLa and CaSKi
cells after the addition of inhibitors for 24 hours. F) Soft agar assay of HeLa and CaSKi cells after transfection of a pool of four specific STAT3 siRNA for 72 hours. G)
Representative western blot of cryptotanshinone dose response after 24 hours. H) Representative western blot after transfection of a pool of four specific STAT3 siRNA
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keratinocytes during the HPV18 lifecycle [23]. We revealed that STAT3 activation correlates
with cervical disease progression. Mechanistically, we demonstrated that JAK2 and MAP
kinases were responsible for phosphorylating STAT3 in HPV containing cells. Despite these
advances, the host factors co-opted by E6 to drive these events were not fully explored. In this
for 72 hours. Samples were probed with antibodies detecting total and phosphorylated STAT3, STAT3 target gene products cyclin D1 and p21 and HPV oncoproteins
E6 and E7. GAPDH served as a loading control. Error bars represent the mean +/- standard deviation of a minimum of three biological repeats. ��P<0.01, ���P<0.001
(Student’s t-test).
https://doi.org/10.1371/journal.ppat.1007835.g012
Fig 13. STAT3 regulates apoptosis in HPV+ cervical cancer. A) Flow cytometric analysis of Annexin V assay in HeLa and CaSKi cells after addition of small
molecule STAT3 inhibitors for 6 and 24 hours. B) Flow cytometric analysis of Annexin V assay in HeLa and CaSKi cells after transfection of a pool of four specific
STAT3 siRNA for 24 hours. C) Representative western blot of HeLa and CaSKi cells after addition of STAT3 inhibitors for 24 hours analysed for PARP cleavage
and Bcl-xL expression. GAPDH served as the loading control. D) Representative western blot of HeLa and CaSKi cells after transfection of a pool of four specific
STAT3 siRNA for 24 hours analysed for PARP cleavage and Bcl-XL expression. GAPDH served as a loading control. E) Quantitative RT-qPCR analysis of HeLa
and CaSKi cells after addition of STAT3 inhibitors for 24 hours for the pro-survival genes BCL2L1 and BIRC5. U6 served as a loading control. F) Quantitative RT-
qPCR analysis of HeLa and CaSKi cells after transfection of a pool of four specific STAT3 siRNA for 72 hours. Cells were analysed for the pro-survival genes
BCL2L1 and BIRC5. U6 served as a loading control. Error bars represent the mean +/- standard deviation of a minimum of three biological repeats. �P<0.05,
��P<0.01, ���P<0.001 (Student’s t-test).
https://doi.org/10.1371/journal.ppat.1007835.g013
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report we identified the upstream signalling pathway responsible for STAT3 phosphorylation
in HPV positive cells. We reveal that E6 regulates a signalling pathway necessary for produc-
tion of the cytokine IL-6. Further, we identified a key role for the small GTPase Rac1 in
Fig 14. Phosphorylated p65, p65 and IL-6 expression correlate with cervical disease progression. A) Scatter dot plot of RT-qPCR analysis of IL-6 mRNA
expression from a panel of cervical cytology samples representing CIN lesions of increasing grade. Five samples from each clinical grade (negative (Neg) and
CIN I-III) were analysed and mRNA levels were normalized to the negative samples. Samples were normalized against U6 mRNA levels. Bars are the
means ± standard deviation. ��P<0.01, ���P<0.001 (Student’s t-test). B) Representative western blots of cervical cytology samples of CIN lesions of increasing
grade analysed for phosphorylated and total p65 and IL-6 protein expression. GAPDH served as a loading control. C-D) Scatter dot plot (left) and box plot
(right) of densitometry analysis of a panel of cytology samples for IL-6 expression. Twenty samples from each clinical grade (neg, CIN I-III) were analysed by
western blot and densitometry analysis was performed using ImageJ. GAPDH was used as a loading control. D) Scatter dot plot of data acquired from the
dataset GSE9750 on the GEO database. Arbitrary values for the mRNA expression of IL-6 in normal cervix (n = 23) and cervical cancer (n = 27) samples were
plotted. E-G) Scatter dot plot of densitometry analysis of a panel of cytology samples for E) phosphorylated p65 and F) total p65. Twenty samples from each
clinical grade (neg, CIN I-III) were analysed by western blot and densitometry analysis was performed using ImageJ. GAPDH was used as a loading control.
G) Scatter dot plot of densitometry analysis of a panel of cytology samples for the ratio of phosphorylated p65 to total p65 expression. Error bars represent the
mean +/- standard deviation. �P<0.05, ��P<0.01, ���P<0.001 (Student’s t-test).
https://doi.org/10.1371/journal.ppat.1007835.g014
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activating NFκB, which induced IL-6 transcription. Ultimately, we deciphered a signalling cir-
cuit critical for STAT3 activation by HPV (Fig 15).
Dysregulation of inflammatory cytokine signalling is an emerging mechanism in transfor-
mation and IL-6 is over-expressed in diverse cancers, correlating with increased STAT3 activ-
ity [21]. IL-6 displays pleiotropic functions, being both pro-inflammatory and
immunosuppressive by interacting with the surrounding stroma of tumours [60]. In HNSCC
and oral squamous cell carcinoma, serum levels of IL-6 are significantly higher than control
patients and serum IL-6 is a potential biomarker for these cancers [61]. Additionally, targeting
IL-6 in combination with EGFR inhibitors such as Cituximab is currently being investigated as
a potential therapy for HNSCC due to the resistance to EGFR inhibition seen in many tumours
[62,63].
In cervical cancer, IL-6 expression promotes tumour proliferation by inducing vascular epi-
thelial growth factor (VEGF)-dependent angiogenesis in a STAT3 dependent manner [64] and
has also been suggested as a potential biomarker [65]. HPV16 and HPV18 E6 oncoproteins
have been demonstrated to be required for the expression and secretion of IL-6 in NSCLC
cells [28]; however, the role of E6 in driving IL-6 expression in cervical cancer is unclear. Fur-
thermore, the contribution of IL-6 to STAT3 activation in cervical cancer remains poorly
defined. The increased phosphorylation of STAT3 in HPV positive cervical cancer cells was
attributed to an increase in IL-6 expression by HPV E6 and the induction of autocrine/para-
crine IL-6/gp130/STAT3 signalling. In cancer cells, EGFR signalling can induce STAT3 activa-
tion [66]; however, the data here identified that blockade of IL-6 or gp130 signalling using
neutralising antibodies abolished STAT3 phosphorylation, suggesting that IL-6/gp130 is the
major determinant for STAT3 phosphorylation in HPV+ cervical cancer cells. Interestingly,
whilst anti-IL-6 treatment did reduce the levels of STAT3 activation, it was not as effective as
when cells were treated with the anti-gp130 antibody. Whilst we cannot discount that this dif-
ference reflects the efficacy of the antibody reagents, an alternative explanation could be pro-
vided by the observation that HPV positive cervical cells show increased expression of a
Fig 15. E6 activates a Rac-1/NFκB mediated STAT3 pathway in HPV+ cervical cancer. Schematic diagram of E6 mediated
activation of STAT3 signalling in HPV+ cervical cancer cells. Through an undetermined mechanism E6 activates a pathway
containing the Rac1 GTPase and its substrate AKT resulting in NFκB phosphorylation and IL-6 transcription. IL-6 functions
in an autocrine and paracrine manner to induce STAT3 phosphorylation and nuclear translocation. Active STAT3 drives a
gene expression programme required for cervical cancer cell proliferation and survival.
https://doi.org/10.1371/journal.ppat.1007835.g015
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number of gp130 binding cytokines (e.g. OSM, LIF and IL-10). These may be responsible for
the residual STAT3 phosphorylation observed [67,68].
We identified NFκB as an essential upstream mediator of IL-6 expression. NFκB is a key
component of the inflammatory response and a key hallmark of cancer [69]. The induction of
inflammation by diverse mechanisms contributes to around 20% of cancers. Previous data
suggests that inflammation induced by HPV infection may contribute to HPV induced cervi-
cal cancers [70,71]. Indeed, several genes known to be induced by the inflammatory response,
including COX-2 [72], are up-regulated in cervical cancer.
The role of NFκB in cervical carcinomas remains controversial, with HPV showing the
potential to both activate and inhibit the transactivation function of NFκB [30,73,74]. HPV E6
has been reported to increase the expression of NFκB components and induce NFκB DNA
binding activity, increasing pro-inflammatory cytokine expression [75]. Additionally, E6 can
reduce the expression of the deubiquitinase CYLD, a known negative regulator of NFκB sig-
nalling, in hypoxic cells [31]. In contrast, E6 has been shown to inhibit NFκB transcriptional
activity, whilst HPV E7 can attenuate p65 nuclear translocation [76]. The data presented here
demonstrate that HPV18 E6 increases the phosphorylation of p65, essential for its nuclear
translocation and transactivation capability. Furthermore, we demonstrate that NFκB is essen-
tial for IL-6 expression in HPV positive cervical cancer cells.
Our study uncovered a signalling circuit linking E6 to NFκB activation and IL-6 produc-
tion. Chief amongst these, we found that the Rac1 GTPase was crucial in mediating the activa-
tion of NFκB. Cells expressing E6 were enriched for the GTP bound form of Rac1, indicating
that E6 has the ability to activate the GTPase function of Rac1. The mechanism by which this
occurs is currently not known, although it does not require interactions with E6AP, p53 or cel-
lular PDZ domain containing proteins as classical E6 mutants deficient in these abilities are
still able to increase IL-6 expression and STAT3 phosphorylation. Use of small molecule inhib-
itors or dominant negative forms of Rac1 support the idea that Rac1 GTPase function and
interaction with downstream targets are crucial for the E6-mediated activation of NFκB. In
this regard, we also identified a role for the protein kinase AKT in HPV-mediated NFκB acti-
vation. AKT can be activated by Rac1 [43] and has been shown to regulate NFκB under certain
circumstances [36,77,78]. In PTEN-null cells, AKT activates NFκB through binding of the
downstream components mTOR and Raptor to the IKK complex, stimulating NFκB activation
[77]. Additionally, AKT can directly phosphorylate and activate IKKα at T23 to enhance p65
phosphorylation [36]. Our data demonstrate that AKT contributes to the phosphorylation of
p65 and the expression on IL-6 in HPV positive cervical cancer; however, inhibition of AKT
only partially reduced IL-6 expression, suggesting alternative components upstream may be
involved in NFκB mediated IL-6 expression. Of particular interest, we noted that CaSKi cells
appeared more sensitive to inhibition of AKT than HeLa cells. In cervical cancer, the PIK3CA
gene is extensively mutated, with the most common mutation (E545K) resulting in constitu-
tive PI3K/AKT signalling [79]. This oncogenic mutation can activate IKK/NFκB signalling
and increase IL-6 secretion and paracrine STAT3 activation in epithelial cells [37]. Interest-
ingly, whilst HeLa cells have wild type PIK3CA, CaSKi cells encode the E545K mutant [80]. It
may therefore be possible that in cells with constitutive PI3K/AKT signalling, AKT inhibition
has a greater contribution to the NFκB/IL-6 signalling axis than in cells expressing wild type
PIK3CA [80].
Loss of active STAT3 had a significant impact on both cervical cancer cell proliferation and
survival. The increased apoptosis observed was coupled with a loss of expression of key pro-
survival factors such as Bcl-XL and Survivin, reinforcing the concept that STAT3 inhibition is
deleterious to HPV cancer cell survival [24,25]. However, it was imperative to obtain a more
comprehensive understanding of the host pathways necessary for STAT3 activation.
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Interestingly, targeting of key upstream factors necessary for the autocrine activation of
STAT3 also impaired proliferation indicating that this signalling circuit is essential in cervical
cancer cells.
The NFκB–IL-6—STAT3 signalling axis is important to cancer biology. We previously
demonstrated increased STAT3 phosphorylation in cervical disease [23] and we now demon-
strate a similar link between IL-6 levels and cervical disease. We noted increased IL-6 mRNA
expression in high-grade cervical disease samples and in cervical cancer samples compared to
healthy controls. Interestingly, we observed that IL-6 protein expression in CIN3 and cervical
cancer clearly stratifies into two sub-populations; IL-6 high and IL-6 low. These findings sug-
gest there may be diversity in the requirement for IL-6 in HPV positive cervical cancers. As
STAT3 can be activated by several soluble factors in cervical cancer cells, such as OSM [67],
EGF [81] and IL-10 [82], it is possible that the IL-6 low cancers might be dependent on these
additional cytokines to maintain active STAT3. Furthermore, IL-6 independent STAT3 activa-
tion can be found in other cancers, including head and neck cancers and haemopoietic cancers
[83–85], suggesting that not all cancers that have high STAT3 activity necessarily have high IL-
6 expression. In diffuse large B-cell lymphoma (DLBCL), a subgroup called the activated B
cell–like (ABC) DLBCL, are characterised by high IL-6 expression and STAT3 activity and,
importantly, are selectively sensitive to JAK inhibition when compared to germinal center B-
cell (GCB) DLBCL [86]. Our data demonstrate that although IL-6 may be essential for the acti-
vation of STAT3 in our cervical cancer cell culture system, the heterogeneity of IL-6 expression
observed in clinical samples of cervical disease and cervical cancers warrants further investiga-
tion to allow the proper stratification of potential therapeutics targeting this pathway.
The data presented here demonstrate that NFκB is essential for the induction of IL-6 and
the autocrine/paracrine induction of STAT3 phosphorylation in HPV+ cervical cancer cells.
We identify that the Rac1 GTPase and protein kinase AKT lie upstream of NFκB/IL-6 signal-
ling. Although therapies are not currently available, strategies to target the NFκB–IL-6 –
STAT3 signalling axis may benefit the treatment of HPV+ cancers.
Methods and materials
Cervical cytology samples
Cervical cytology samples were obtained from the Scottish HPV Archive (http://www.shine/
mvm.ed.ac.uk/archive.shtml), a biobank of over 20,000 samples designed to facilitate HPV
associated research. The East of Scotland Research Ethics Service has given generic approval to
the Scottish HPV Archive as a Research Tissue Bank (REC Ref 11/AL/0174) for HPV related
research on anonymised archive samples. Samples are available for the present project though
application to the Archive Steering Committee (HPV Archive Application Ref 0034). RNA
and protein were extracted from the samples using Trizol as described by the manufacturer
(ThermoFischer Scientific, USA) and analysed as described.
Cell culture
C33A (HPV negative cervical carcinoma), DoTc2 4510 (HPV negative cervical carcinoma),
SiHa (HPV16 positive cervical squamous carcinoma), CaSKi (HPV16 positive cervical squa-
mous carcinoma), SW756 (HPV18 positive squamous carcinoma) and HeLa (HPV18 positive
cervical epithelial adenocarcinoma) cells were purchased from ATCC and grown in Dulbec-
co’s modified Eagle’s media (DMEM) supplemented with 10% Foetal Bovine Serum (FBS)
(ThermoFischer Scientific, USA) and 50 U/ml penicillin/streptomycin (Lonza). NHK cells
were purchased from Lonza and maintained as described [7].
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Inhibitors and cytokines
The IKKα/β inhibitor IKK inhibitor VII was purchased from Calbiochem and used at a final
concentration of 5 μM unless otherwise stated. The AKT1/2 inhibitor AKT VIII was purchased
from Calbiochem and used at a final concentration of 5 μM unless otherwise stated. Recombi-
nant human IL-6 was purchased from R&D Systems and used at a final concentration of 20
ng/mL unless otherwise stated. Recombinant TNFα was purchased from PeproTech EC Ltd
and used at a final concentration of 10 ng/mL. All compounds were used at concentrations
required to minimise potential off-target activity. Neutralising IL-6 antibody (ab6628) was
purchased from Abcam and used at a final dilution of 1:400. Neutralising gp130 antibody
(MAB228) was purchased from R&D Systems and used at a final concentration of 1 μg/mL.
Plasmids and siRNAs
Plasmids expressing HPV18 E6 sequences were amplified from the HPV18 genome and cloned
into peGFP-C1 with SalI and XmaI restriction enzymes [23]. The plasmid driving Firefly lucif-
erase from the IL-6 promoter was a kind gift from Prof Derek Mann (University of Newcastle)
and used as previously described [87]; the ConA promoter (that contains tandem NFκB
response elements) [88] and a constitutive Renilla luciferase reporter (pRLTK) were previously
described [87]. The IκBα S33/36A mutant was a kind gift from Prof Ronald Hay (University of
Dundee). pLNCX myr HA AKT1 K179M (AKT-DN) vector was purchased from Addgene
(Addgene, 9006) and murine retrovirus envelope and GAG/polymerase plasmids were kindly
provided by Professor Greg Towers (University College London). pcDNA-GFP-Rac1-T17N
(Rac1-DN) was kindly provided by Professor Adrian Whitehouse (University of Leeds).
MSCV-HA-HPV18 E6 was kindly provided by Dr Elizabeth White (University of Pennsylva-
nia). For siRNA experiments, two siRNA sequences specifically targeting HPV18 E6 were pur-
chased from GE Healthcare with the following sequences: 5’CUAACACUGGGUUAUACAA‘3
and 5’CTAACTAACACTGGGTTAT‘3. For HPV16, a single siRNA targeting the HPV16 E6
protein was purchased from Santa Cruz Biotechnology (SCBT; sc-156008). For each experi-
ment, 40 nM of pooled siRNA was used and cell lysates were harvested after 72 hours.
Transfections and mammalian cell lysis
Transient transfections were performed with a DNA to Lipofectamine 2000 (ThermoFischer)
ratio of 1:2.5. 48 h post transfection, cells were lysed in Leeds lysis buffer for western blot [88].
Colony formation assay
48 hr post-transfection, cells were trypsinised and reseeded in a six well plate at 500 cells per
well and left to incubate for 14–21 days. Colonies were then stained (1% crystal violet, 25%
methanol) and colonies were counted manually. Each experiment was repeated a minimum of
3 times.
Soft agar assay
Cells were transfected as required. 60 mm dishes were coated with a layer of 1% agarose (Ther-
moFischer Scientific, USA) in 2X DMEM (ThermoFischer Scientific, USA) supplemented
with 20% FBS. 48 hr post-transfection, cells were trypsinised and added to 0.7% agarose in 2X
DMEM (ThermoFischer Scientific, USA) supplemented with 20% FBS at 1000 cells/mL. Once
set, DMEM supplemented with 10% FBS and 50 U/mL penicillin was added. The plates were
then incubated for 14–21 days. Each experiment was repeated at least three times unless stated
otherwise. Visible colonies were counted manually.
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Annexin V assay
Annexin V apoptosis assay (TACS Annexin V kit; 4830-250-K) was performed as indicated on
the product datasheet. Briefly, cells were seeded in 6 well plates at a density of 1 x 106 cells/mL
and were treated as required per experiment. Cells were then trypsinised and collected by cen-
trifugation at 700 x g for 5 mins. Cells were then washed in cold PBS and re-centrifuged. 1x106
cells were then incubated in 100 μL Annexin V reagent (10 μL 10 x binding buffer, 10 μL pro-
pidium iodide, 1 μL Annexin V-FITC (diluted 1 in 500) and 880 μL ddH2O) for 15 mins at
room temperature in the dark. 400 μL of 1 x binding buffer was then added before analysis by
flow cytometry. Samples were processed on an LSRFortessaTM cell analyzer (BD) and the PI
histograms analysed on modfit software.
Western blotting
Total protein was resolved by SDS-PAGE (10–15% Tris-Glycine), transferred onto Hybond
nitrocellulose membrane (Amersham biosciences) and probed with antibodies specific for
phospho-STAT3 (S727) (ab32143, abcam), phospho-STAT3 (Y705) (9131, Cell Signalling
Technology (CST)), STAT3 (124H6: 9139, CST), phospho-NFκB p65 (S536) (93H1; 3033,
CST), NFκB p65 (D14E12; 8242, CST), phospho-AKT (T308) (244F9; 4056, CST), phospho-
AKT (S473) (D9E; 4060, CST), AKT (9272, CST), IL-6 (ab6672, abcam), HA (HA-7, Sigma
H9658), GFP (B-2: sc-9996, SCBT), FLAG (F3165, Sigma), GAPDH (G-9, SCBT), PARP-1
(9542, CST) and Bcl-xL (2764, CST). Western blots were visualized with species-specific HRP
conjugated secondary antibodies (Sigma) and ECL (Thermo/Pierce). Densitometry analysis
was performed using ImageJ analysis software (NIH, USA).
Retrovirus transduction
pLNCX AKT vector (Addgene, 9006) and MSCV-HA-18E6 were transfected into HEK293TT
cells with murine retrovirus envelope and GAG/polymerase plasmids (kindly provided by Pro-
fessor Greg Towers, University College London) using PEI transfection reagent as previously
described [23]. After 48 hours the media was removed from the HEK293TT cells and added to
HeLa cells for 16 hours. After this time, the virus was removed and replaced with DMEM and
cells were harvested 48 hours after transduction.
Quantitative real-time PCR
Total RNA was extracted using the E.Z.N.A. Total RNA Kit I (Omega Bio- Tek) according to
the manufacture’s protocol. One μg of total RNA was DNase treated following the RQ1
RNase-Free DNase protocol (Promega) and then reverse transcribed with a mixture of random
primers and oligo(dT) primers using the qScriptTM cDNA SuperMix (Quanta Biosciences)
according to instructions. RT- qPCR was performed using the QuantiFast SYBR Green PCR
kit (Qiagen). The PCR reaction was conducted on a Corbett Rotor-Gene 6000 (Qiagen) as fol-
lows: initial activation step for 10 min at 95˚C and a three-step cycle of denaturation (10 sec at
95˚C), annealing (15 sec at 60˚C) and extension (20 sec at 72˚C) which was repeated 40 times
and concluded by melting curve analysis. The data obtained was analysed according to the
ΔΔCt method using the Rotor-Gene 6000 software [89]. Specific primers were used for each
gene analysed. U6 served as normaliser gene.
Luciferase reporter assays
Cells were seeded into 12 well dishes and transfected the following day using PEI with reporter
plasmids expressing firefly luciferase under the control of the IL-6 promoter or the ConA
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promoter, which contains tandem repeats of a κB-response element [87,90]. Where appropri-
ate, cells were co-transfected with plasmids expressing GFP or GFP-E6. To normalise for
transfection efficiency, pRLTK Renilla luciferase reporter plasmid was added to each transfec-
tion. After 24 hours, samples were lysed in passive lysis buffer (Promega) and activity mea-
sured using a dual-luciferase reporter assay system (Promega) as described [91].
Immunofluorescent staining
Cells were seeded onto coverslips and, 24 hr later, were transfected as required. 24 hr after
transfection, cells were fixed with 4% paraformaldehyde for 10 min and then permeabilised
with 0.1% (v/v) Triton for 15 minutes. Cells were then incubated in primary antibodies in PBS
with 4% BSA overnight at 4˚C. Primary antibodies were used at a concentration of 1:400. Cells
were washed thoroughly in PBS and then incubated with Alex-fluor conjugated secondary
antibodies 594 and Alexa 488 (1:1000) (Invitrogen) in PBS with 4% BSA for 2 hours. DAPI
was used to visualise nuclei. Coverslips were mounted onto slides with Prolong Gold (Invitro-
gen). Quantification of nuclear localisation was quantified as described [92].
ELISA
The human IL-6 DuoSet1 ELISA was purchased from R&D Systems and was used according
to the manufacturer’s instructions.
Rac1 activation assay
The activation of Rac1 was determined by pulldown assay as previously described [51] and fol-
lowing the manufacturer’s instructions (Cell Biolabs). Cell lysates were incubated with PAK
PBD agarose beads, which have a high affinity for GTP-Rac1. Affinity precipitated activated
Rac1-GTP levels were then analysed by immunoblotting using a Rac1 specific antibody (Cell
Biolabs).
Microarray analysis
For microarray analysis, a dataset of 27 cervical cancer cases and 23 normal cervix samples was
utilised. Microarray data was obtained from GEO database accession number GSE9750.
Statistical analysis
Where indicated, data was analysed using a two-tailed, unpaired Student’s t-test.
Supporting information
S1 Fig. HPV18 E6 induces IL-6 expression in primary keratinocytes. A) Normal human ker-
atinocytes (NHK) were transfected with GFP or GFP tagged HPV18 E6 and analysed for IL-6
mRNA expression by RT-qPCR. Samples were normalized against U6 mRNA levels. B) Repre-
sentative western blot of NHK cells transfected with GFP or GFP tagged HPV18 E6 and ana-
lysed for the expression of IL-6 protein. Expression of GFP was confirmed with an antibody
against GFP whilst the GFP E6 fusion was detected using a HPV18 E6 antibody. GAPDH
served as a loading control. C) NHK cells were transfected with GFP or GFP tagged HPV18
E6. The culture medium was analysed for IL-6 protein by ELISA. Data are representative of at
least three biological independent repeats. Error bars represent the mean +/- standard devia-
tion of a minimum of three biological repeats. �P<0.05, (Student’s t-test).
(TIFF)
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S2 Fig. HPV16 E6 induces IL-6 expression. A) CaSKi cells were transfected with HPV16 E6
specific siRNA and analysed for IL-6 mRNA expression by RT-qPCR. Samples were normal-
ized against U6 mRNA levels. B) Representative western blot of CaSKi cells transfected with a
pool of two specific siRNAs against HPV16 E6 and analysed for the expression of IL-6. Knock-
down of HPV16 E6 was confirmed using antibodies against HPV16 E6 and p53. GAPDH
served as a loading control. C) CaSKi cells were transfected with a pool of two specific siRNAs
against HPV16 E6. The culture medium was analysed for IL-6 protein by ELISA. Data are rep-
resentative of at least three biological independent repeats. Error bars represent the mean +/-
standard deviation of a minimum of three biological repeats. �P<0.05, ���P<0.001 (Student’s
t-test).
(TIFF)
S3 Fig. The p53, E6AP and PDZ domain binding properties of E6 are not required for
induction of IL-6 expression in cervical cells. A) C33A cells were transfected with GFP, GFP
tagged HPV18 E6 wildtype, HPV18 E6 ΔPDZ, HPV18 E6 F4V and HPV18 L52A. Lysates were
probed with antibodies against IL-6 and GAPDH served as a loading control. Expression of
the GFP E6 fusions was confirmed by anti-GFP western blot and p53 western blot validated
the inability of the F4V and L52A mutants to degrade p53.
(TIFF)
S4 Fig. Activation of NFκB by TNFα induces IL-6 expression and STAT3 nuclear translo-
cation. A) Representative western blot of C33A cells treated with 20 ng/mL recombinant
human TNFα for the indicated time points. Cell lysates were analysed for phosphorylated
and total p65, phosphorylated and total STAT3 and IL-6 expression. GAPDH served as a
loading control. Data are representative of at least three biological independent repeats. B)
C33A cells treated with 20 ng/mL recombinant human TNFα for 60 mins were fixed and
were analysed by immunofluorescence staining for total STAT3 (green) and total p65 (red)
and counterstained with DAPI to highlight the nuclei (blue in the merged panels). Scale bar
20 μm.
(TIFF)
S5 Fig. NFκB is required for STAT3 activity in HPV16 positive cervical cancer cells. A)
Representative western blot of CaSKi cells treated with increasing doses of IKKi. Cell lysates
were analysed for the expression of phosphorylated and total p65, phosphorylated and total
STAT3 and IL-6 expression. GAPDH served as a loading control. B) Representative western
blot of CaSKi cells transfected with mutant IκB (IκBm). Cell lysates were analysed as in A).
(TIFF)
S6 Fig. Quantification of nuclear STAT3 from Fig 7. A) Scatter dot plot of percentage
nuclear STAT3 from Fig 7E. Data represents the percentage nuclear localisation of STAT3
from 15 cells from three independent experiments. Nuclear localisation was calculated using
ImageJ [92]. B) Scatter dot plot of percentage nuclear STAT3 from Fig 7F. Data represents the
percentage nuclear localisation of STAT3 from 15 cells from three independent experiments.
Nuclear localisation was calculated using ImageJ [92]. Error bars represent the mean +/- stan-
dard deviation. NS = not significant, ���P<0.001 (Student’s t-test).
(TIFF)
S7 Fig. AKT is required for STAT3 activity in HPV16 positive cervical cancer cells. A) Rep-
resentative western blot of CaSKi cells treated with increasing doses of the AKTi. Cell lysates
were analysed for the levels of phosphorylated and total AKT and STAT3 and IL-6 protein.
GAPDH served as a loading control. B) Representative western blot of CaSKi cells transfected
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with dominant negative AKT (AKT-DN). Cell lysates were analysed as in A).
(TIFF)
S8 Fig. Quantification of nuclear STAT3 from Fig 9. A) Scatter dot plot of percentage
nuclear STAT3 from Fig 9E. Data represents the percentage nuclear localisation of STAT3
from 15 cells from three independent experiments. Nuclear localisation was calculated using
ImageJ [92]. B) Scatter dot plot of percentage nuclear STAT3 from Fig 9F. Data represents the
percentage nuclear localisation of STAT3 from 15 cells from three independent experiments.
Nuclear localisation was calculated using ImageJ [92]. Error bars represent the mean +/- stan-
dard deviation. NS = not significant, ���P<0.001 (Student’s t-test).
(TIFF)
S9 Fig. Rac1 is required for STAT3 activity in HPV16 positive cervical cancer cells. A) Rep-
resentative western blot of CaSKi cells treated with increasing doses of NSC. Cell lysates were
analysed for the levels of phosphorylated and total STAT3 and IL-6 protein expression.
GAPDH served as a loading control. B) Representative western blot of CaSKi cells transfected
with Rac1 N17 (Rac1-DN). Cell lysates were analysed as in A).
(TIFF)
S10 Fig. Quantification of nuclear STAT3 from Fig 11. A) Scatter dot plot of percentage
nuclear STAT3 from Fig 11E. Data represents the percentage nuclear localisation of STAT3
from 15 cells from three independent experiments. Nuclear localisation was calculated using
ImageJ [92]. B) Scatter dot plot of percentage nuclear STAT3 from Fig 11F. Data represents
the percentage nuclear localisation of STAT3 from 15 cells from three independent experi-
ments. Nuclear localisation was calculated using ImageJ [92]. Error bars represent the mean
+/- standard deviation. NS = not significant, ���P<0.001 (Student’s t-test).
(TIFF)
S11 Fig. NFκB, AKT and Rac1 contribute to the proliferation of HPV positive cervical can-
cer cells. A) Colony formation assay (anchorage dependent growth) of HeLa and CaSKi cells
after treatment with IKKi or transfection with IkBm. B) Colony formation assay (anchorage
dependent growth) of HeLa and CaSKi cells after treatment with AKTi or transfection with
AKT-DN. C) Colony formation assay (anchorage dependent growth) of HeLa and CaSKi cells
after treatment with NSC or transfection with Rac1-DN. D) Soft agar assay (anchorage inde-
pendent growth) of HeLa cells after treatment with the indicated inhibitors or transfection
with the indicated constructs. E) Soft agar assay of CaSKi cells after treatment with the indi-
cated inhibitors or transfection with the indicated constructs. Error bars represent the mean
+/- standard deviation from the appropriate control (DMSO or pcDNA) of a minimum of
three biological repeats. �P<0.05, ��P<0.01, ���P<0.001 (Student’s t-test).
(TIFF)
S12 Fig. STAT3 contributes to IL-6 expression in HPV positive cervical cancer cells. A)
HeLa and CaSKi cells were transfected with a pool of four specific siRNAs against STAT3 and
analysed for IL-6 mRNA expression by RT-qPCR. Samples were normalized against U6 mRNA
levels. B) Representative western blot of HeLa and CaSKi cells transfected with a pool of four
specific siRNAs against STAT3. Cell lysates were analysed for total STAT3 and IL-6. GAPDH
served as a loading control. C) HeLa and CaSKi cells were transfected with a pool of four spe-
cific siRNAs against STAT3. The culture medium was then analysed for IL-6 expression by
ELISA. Data are representative of at least three biological independent repeats. Error bars repre-
sent the mean +/- standard deviation. �P<0.05, ��P<0.01, ���P<0.001 (Student’s t-test).
(TIFF)
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